you are viewing a single comment's thread.
They need a good analyst on the topic/company for sure, or better yet a pharma deal around one or more of these GPCRs. Press release wasn't bad, and I'm sure Omeros looked at what they could say without facing potential legal issues, but it failed (in my mind) to really elucidate what this could mean for the Company.
The street is littered with bankrupt companies that failed to monetize their ideas. So I agree that a pharma deal is needed for the street to figure out how much to value the company and it would alleviate cash burn fears.
Seem to remember an option agreement or $-sharing deal with owner of gpcr IP technology if OMER partners with pharma. What is % to OMER of any pharma upfront/milestone payments?